Novogene (UK) Company Limited
Registered name: NOVOGENE (UK) COMPANY LIMITED
Novogene (UK) Company Limited made £38.2m revenue and £2.8m profit in the year to 31 Dec 2025. read from filing text
Novogene (UK) Company Limited’s revenue grew 5% to £38.2m in the year to 31 Dec 2025, with £2.8m profit and 68 employees. The company is classified under “research and experimental development on biotechnology” and is based in Cambridge; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Cambridge, East of England
- Age
- 11 yrs · since 2014
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The ultimate controlling party is R Li.”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | Full P&Lread from filing text | Full P&Lread from filing text | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | ||||
| Revenue (turnover) | £31.4m | £38.5m | £36.3m | £38.2m |
| Cost of sales | £20.3m | £24.1m | £23.4m | £24m |
| Gross profit | £11.1m | £14.5m | £13m | £14.2m |
| Operating profit | £1.9m | £82.6k | £768k | £2.7m |
| Profit before tax | £2.1m | £1.2m | £2.2m | £3.7m |
| Profit after tax | £1.7m | £922k | £1.7m | £2.8m |
| Profit (best available) | £1.7m | £922k | £1.7m | £2.8m |
| Staff costs | £3.6m | £3.9m | £4.1m | £4m |
| Employees (average) | 92 | 86 | 79 | 68 |
| Ratios | ||||
| Profit margin | 5.5% | 2.4% | 4.6% | 7.3% |
| Gross margin | 35.3% | 37.5% | 35.7% | 37.3% |
| Revenue per employee | £341k | £448k | £460k | £562k |
| Profit per employee | £18.7k | £10.7k | £21.1k | £40.9k |
| Cash conversion | — | 2107% | −119.2% | 985.2% |
| Growth (year on year) | ||||
| Revenue growth | — | ▲22.6% | ▼5.7% | ▲5.1% |
| Profit growth | — | ▼46.4% | ▲81% | ▲66.7% |
| Headcount growth | — | ▼6.5% | ▼8.1% | ▼13.9% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £39.2m | £5.2m | £3.1m | £494k |
| Net assets | £5.6m | £6m | £7.7m | £5.5m |
| Fixed assets | £2.8m | £3.6m | £2.5m | £1.7m |
| Current assets | £43m | £41.1m | £44.1m | £31.2m |
| Debtors | £980k | £1.6m | £1.4m | £1.7m |
| Deferred income | £86.4k | £42.4k | £55k | £66k |
| Cash from operations | — | £1.7m | −£916k | £27.1m |
| Source | FullAccounts · bulk data Sep 2024 | FullAccounts · bulk data Sep 2024 | FullAccounts · bulk data Aug 2025 | FullAccounts · bulk data Sep 2026 |
How the business works
- Profit margin
- 7.3%
- Profit ÷ revenue.
- Gross margin
- 37.3%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £562k
- Revenue ÷ average employees.
- Profit per employee
- £40.9k
- Profit ÷ average employees.
- Cash conversion
- 985.2%
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 4.6%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 0.2%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 4.5%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼29%
- Now £5.5m
- Cash at bank
- ▼84%
- Now £494k
- Headcount
- ▼14%
- Now 68
- Deferred income
- ▲20%
- Now £66k
- Fixed assets
- ▼31%
- Now £1.7m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Novo Nordisk Research and Development UK LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £52.2m
- Profit
- £2.5m
- Staff
- 181
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit £2.8m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.